- ►thelancet.com R Maini, EW St Clair, F Breedveld, D Furst, … - The Lancet, 1999 - Elsevier At 30 weeks, the American College of Rheumatology (20) response criteria,
representing a 20% improvement from baseline, were achieved in 53, 50, 58, and
52% of patients receiving 3 mg/kg every 4 or 8 weeks or 10 mg/kg every 4 or ... Cited by 1342 - Related articles - BL Direct - All 5 versions
- ►stanford.edu [PDF] JM Bathon, RW Martin, RM Fleischmann, JR … - The New England journal of medicine, 2000 - nejm.highwire.org Methods We treated 632 patients with early rheumatoid arthritis with either
twice-weekly subcutaneous etanercept (10 or 25 mg) or weekly oral methotrexate
(mean, 19 mg per week) for 12 months. Clinical response was defined as the ... Cited by 1205 - Related articles - BL Direct - All 11 versions
EHS Choy, GS Panayi - The New England journal of medicine, 2001 - nejm.highwire.org Efforts to develop safer and more effective treatments for rheumatoid arthritis
that are based on an improved understanding of the role of inflammatory
mediators are beginning to bear fruit. Treatments such as etanercept, a ... Cited by 938 - Related articles - BL Direct - All 5 versions
PJ Mease, BS Goffe, J Metz, A VanderStoep, … - The Lancet, 2000 - Elsevier In this 12 week study, 26 (87%) of etanercept-treated patients met the PsARC,
compared with seven (23%) of placebo-controlled patients. The ARC20 was achieved
by 22 (73%) of etanercept-treated patients compared with four (13%) of ... Cited by 898 - Related articles - All 7 versions
- ►sepeap.org [PDF] L Klareskog, D van der Heijde, JP de Jager, … - The Lancet, 2004 - Elsevier Methods In a double-blind, randomised, clinical efficacy, safety, and
radiographic study, 686 patients with active rheumatoid arthritis were randomly
allocated to treatment with etanercept 25 mg (subcutaneously twice a week), ... Cited by 646 - Related articles - All 9 versions
DJ Lovell, EH Giannini, A Reiff, GD Cawkwell, … - The New England journal of medicine, 2000 - nejm.highwire.org Methods Patients 4 to 17 years old received 0.4 mg of etanercept per kilogram of
body weight subcutaneously twice weekly for up to three months in the initial,
open-label part of a multicenter trial. Those who responded to treatment ... Cited by 605 - Related articles - All 5 versions
- ►umh.es [PDF] JM Kremer, R Westhovens, M Leon, E Di … - The New England journal of medicine, 2003 - nejm.highwire.org Background Effective new therapies are needed for rheumatoid arthritis. Current
therapies target the products of activated macrophages; however, T cells also
have an important role in rheumatoid arthritis. A fusion protein — ... Cited by 510 - Related articles - BL Direct - All 10 versions
JD Gorman, KE Sack, JC Davis Jr - The New England journal of medicine, 2002 - nejm.highwire.org N Engl J Med, Vol. 346, No. 18 · May 2, 2002 · www.nejm.org · ... TREATMENT
OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a ... J
ENNIFER D. G ORMAN , MD, K ENNETH E. S ACK , MD, AND J OHN C. D AVIS , J R ... Cited by 510 - Related articles - BL Direct - All 6 versions
MC Genovese, JM Bathon, RW Martin, RM … - Arthritis Rheum, 2002 - aramis.stanford.edu Mark C. Genovese,1 Joan M. Bathon,2 Richard W. Martin,3 Roy M. Fleischmann,4
John R. Tesser,5 Michael H. Schiff,6 Edward C. Keystone,7 Mary Chester Wasko,8
Larry W. Moreland,9 Arthur L. Weaver,10 Joseph Markenson,11 Grant W. ... Cited by 513 - Related articles - View as HTML - BL Direct - All 9 versions
- ►umh.es [PDF] CL Leonardi, JL Powers, RT Matheson, BS … - The New England journal of medicine, 2003 - nejm.highwire.org From the Saint Louis University School of Medicine, St. Louis (CLL); Radiant Re-
search, Scottsdale, Ariz. (JLP); Oregon Medical Research Center, Portland (RTM);
Minor and James Medical Center, Seattle (BSG); Amgen, Thousand Oaks, Calif. ... Cited by 498 - Related articles - BL Direct - All 7 versions
